Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Strauss

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Clinical Sarcoma Research|June 18, 2016
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop ReportLeo Kager, Jeremy Whelan, Uta Dirksen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Clinical Sarcoma Research|June 18, 2016
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop ReportLeo Kager, Jeremy Whelan, Uta Dirksen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Pageof 2